Clinical trials: Organophosphate Exposure

Organophosphate Exposure

An Exploratory Phase 1 Microdose Study of PRX-105

• Completed
• Age: 18 to 45 years
• Early Phase 1
• Injection or infusion

Exploratory phase 1, first in human, open label, non-randomized, single-dose study of PRX-105, administered intravenously by slow bolus injection to 10 healthy volunteers.

Trial name

NCT01093859

Testing

PRX-105

Where

Israel

Volunteers

10 people, healthy volunteers welcome

Sponsor

Protalix